RedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59 jaimeuss_admin 17 בSeptember 2018 Research 0 Comments Continue Reading
BiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15 jaimeuss_admin 30 בAugust 2018 Research 0 Comments Continue Reading